CN110627912B - A biomimetic fiber network antibody self-assembly material and its preparation method and application - Google Patents
A biomimetic fiber network antibody self-assembly material and its preparation method and application Download PDFInfo
- Publication number
- CN110627912B CN110627912B CN201910995134.4A CN201910995134A CN110627912B CN 110627912 B CN110627912 B CN 110627912B CN 201910995134 A CN201910995134 A CN 201910995134A CN 110627912 B CN110627912 B CN 110627912B
- Authority
- CN
- China
- Prior art keywords
- self
- fiber network
- assembly material
- phe
- asp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种仿生纤维网络抗体自组装材料及其制备方法和应用，所述仿生纤维网络抗体自组装材料包括通过酰胺键依次连接的靶向单元、纤维单元和疏水单元，其化学结构为R1‑R2‑R3；其中，R2来自于分子内具有多重氢键的纤维肽；R3来自于肿瘤靶向肽。本发明所述自组装材料仿生细胞外基质形成过程，利用纳米多肽在肿瘤细胞表面与受体蛋白结合形成纤维网络结构，调控膜蛋白的聚集，作为纤维网络多肽抗体，可以实现多价键结合，靶向结合能力显著增强，且纤维网络抗体作用效果更加持久。同时纤维网络抗体不进入细胞，避免了脱敏耐药性的发生。
The invention relates to a biomimetic fiber network antibody self-assembly material, a preparation method and application thereof. The biomimetic fiber network antibody self-assembly material comprises a targeting unit, a fiber unit and a hydrophobic unit sequentially connected by an amide bond, and its chemical structure is R 1 -R 2 -R 3 ; wherein, R 2 is derived from a fibrinopeptide with multiple hydrogen bonds in the molecule; R 3 is derived from a tumor-targeting peptide. The self-assembly material biomimetic extracellular matrix formation process of the present invention utilizes nano-polypeptides to combine with receptor proteins on the surface of tumor cells to form a fibrous network structure to regulate the aggregation of membrane proteins. The targeted binding ability is significantly enhanced, and the effect of the fiber network antibody is more durable. At the same time, the fibronectin antibody does not enter the cell, which avoids the occurrence of desensitization and drug resistance.
Description
Technical Field
The invention relates to the field of biomedicine, in particular to a self-assembly material and a preparation method and application thereof, and particularly relates to a bionic fiber network antibody self-assembly material and a preparation method and application thereof.
Background
Tumor refers to a new organism formed by local tissue cell proliferation under the action of various carcinogenic factors, because the new organism mostly presents space occupying block-shaped protrusion, also called as neoplasm. The serious harm to the health of people caused by tumors, and the high death rate of the tumors mainly causes the rapid growth, the rapid metastasis and the strong invasion capacity of the tumors. Tumor metastasis or invasion is an extremely complex process in which tumor metastasis can be inhibited by inhibiting the activity of metallomatrix proteases, which degrade the extracellular matrix as a major factor leading to tumor metastasis, but this approach has little effect. Meanwhile, in recent years, the rapid development of nano materials leads the nano materials to be widely regarded, with the continuous deepening of nano technology in the years, the characteristics of nano substances are continuously discovered, the application field is also deepened, and the polypeptide self-assembly nano materials have good biocompatibility and mechanical property and are widely applied to biological imaging and treatment.
CN107049991A discloses a novel mesoporous silica nano drug delivery system for inhibiting tumor cell migration and invasion in a dual-targeting manner and a preparation method thereof, wherein the mesoporous silica nano drug delivery system takes a cyclic pentapeptide-hyaluronic acid as a targeting material, adriamycin as a model drug and mesoporous silica as a drug carrier. The drug delivery system can improve the inhibition rate of tumor cell migration and invasion; the preparation process is simple and has wide application prospect.
CN109091678A discloses a preparation method and application of a supermolecule assembly for inhibiting tumor invasion and diffusion, wherein a building unit takes hyaluronic acid modified by beta-cyclodextrin as a main body and magnetic nanoparticles modified by octapeptide as an object, and a nano supermolecule fiber aggregate is built through the interaction of the supermolecule main body and the object. The supermolecule assembly is directionally aggregated under the induction of a geomagnetic field or a weak magnetic field, and can be subjected to light control induction to aggregate the supermolecule assembly; the assembly can also specifically attract cancer cells in a nanofiber reticular structure, and can damage mitochondria, so that the assembly has wide application prospect in the field of tumor treatment, especially in the aspect of actively inhibiting the invasion and diffusion of tumor cells.
In summary, the prior art has few strategies for inhibiting tumor metastasis and invasion, and therefore, it is very meaningful to develop a novel therapeutic strategy with significant efficacy, which can inhibit tumor growth, metastasis and invasion.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a self-assembly material and a preparation method and application thereof, and particularly provides a bionic fiber network antibody self-assembly material and a preparation method and application thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the invention provides a bionic fiber network antibody self-assembly material, which comprises targeting units R sequentially connected through amido bonds3Fiber unit R2And a hydrophobic unit R1The three units are connected through amide bonds, and the chemical structure of the three units is shown as the formula (I):
R1-R2-R3formula (I);
wherein R is2From fibrous peptides having multiple hydrogen bonds within the molecule; r3Derived from a tumor targeting peptide.
Compared with the prior antibody technology, the invention provides a new idea and a new method of a novel bionic antibody, the fiber peptide in the self-assembly material has good biocompatibility and self-assembly capability, and the bionic extracellular matrix forming process utilizes the combination of the nano-polypeptide and receptor protein on the surface of tumor cells to form a fiber network structure, regulates and controls the aggregation of membrane protein, and the fiber network polypeptide antibody can be used as a fiber network polypeptide antibody to realize the combination of multivalent bonds. More importantly, compared with the desensitization effect and possible drug resistance generated by the traditional antibody combining endocytosis, the fiber network antibody does not enter cells, and the occurrence of desensitization drug resistance is avoided. Therefore, the nano-polypeptide bionic fiber network antibody has a great prospect in application to tumor resistance, can efficiently inhibit the growth, invasion and metastasis of tumors, and has a wide application prospect.
The tumor targeting peptide in the self-assembly material can realize active targeting on a tumor part, and improve the biological safety and bioavailability of the material.
Preferably, said R is1The chemical structure of (a) is selected from any one of the following structures:
wherein n1, n2 and n3 are respectively and independently selected from any integer of 1-18 (such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18); the dotted line represents the attachment site. n1, n2 and n3 represent the number of carbon atoms in an alkyl chain.
From the above, in the present invention, the hydrophobic material
Carboxy and R in (1)2The amino groups of the first amino acid in the polypeptide sequence are connected through amido bond, R2Carboxyl and R of terminal amino acid in polypeptide sequence3The amino groups of the first amino acids in the polypeptide sequence are connected through amido bonds.
Preferably, said R is2Any one of the following polypeptide sequences:
Lys-Leu-Val-Phe-Phe；Leu-Pro-Phe-Phe-Asp。
the structural formulas of the polypeptide sequences are respectively shown as follows:
Lys-Leu-Val-Phe-Phe
Leu-Pro-Phe-Phe-Asp
preferably, said R is3Any one of the following polypeptide sequences:
Asp-Gly-Arg；Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val。
the structural formulas of the polypeptide sequences are respectively shown as follows:
Asp-Gly-Arg
Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val
as a preferable scheme of the invention, the chemical structural general formula of the bionic fiber network antibody self-assembly material is R1-R2-R3Wherein said R is2Derived from the polypeptide sequence Lys-Leu-Val-Phe-Phe, said R3Derived from the polypeptide sequence Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val, said R1Has a chemical structure of
The dotted line indicates the attachment site.
On the other hand, the invention provides a preparation method of the bionic fiber network antibody self-assembly material, which comprises the following steps:
the bionic fiber network antibody self-assembly material is synthesized by taking amino acid with protected terminal amino group and side chain amino group and hydrophobic material as raw materials through a solid phase synthesis method.
The preparation method of the bionic fiber network antibody self-assembly material provided by the invention is synthesized according to a standard polypeptide solid phase synthesis method (SPPS). For example, the following steps can be followed:
(1) swelling the carrier resin;
(2) adopting amino acid with Fmoc protection obtained from terminal amino group, Boc protection obtained from side chain amino group and hydrophobic material as raw materials, firstly, according to R3Amino acid sequence of (1), R3Adding a first amino acid to the carrier resin, and performing coupling reaction and connection with the carrier resin; removing R3Fmoc protecting group on the first amino acid, reacting R3A second amino acid with R3The first amino acid is coupled and ligated; until R is completed3Condensation of all amino acids in (1);
(3) removing R3Fmoc protecting group of the last amino acid, according to R2Amino acid sequence of (1), R2First amino acid with R3The last amino acid is subjected to coupling reaction and ligation; removing R2Fmoc protecting group on the first amino acid, reacting R2A second amino acid with R2The first amino acid is coupled and ligated; until R is completed2Condensation of all amino acids in (1);
(4) removing R2Fmoc protecting group of the last amino acid, the carboxyl end of the hydrophobic molecule and R2The last amino acid is subjected to coupling reaction and ligation;
(5) and (4) removing the product obtained in the step (4) from the carrier resin to obtain the bionic fiber network antibody self-assembly material.
In another aspect, the invention provides an application of the bionic fiber network antibody self-assembly material in preparing a medicament for inhibiting tumor growth, metastasis or invasion.
Compared with the prior art, the invention has the following beneficial effects:
compared with the prior antibody technology, the invention provides a new idea and a new method of a novel bionic antibody, the fiber peptide in the self-assembly material has good biocompatibility and self-assembly capability, and the bionic extracellular matrix forming process utilizes the combination of the nano-polypeptide and receptor protein on the surface of tumor cells to form a fiber network structure, regulates and controls the aggregation of membrane protein, and the fiber network polypeptide antibody can be used as a fiber network polypeptide antibody to realize the combination of multivalent bonds. More importantly, compared with the desensitization effect and possible drug resistance generated by the traditional antibody combining endocytosis, the fiber network antibody does not enter cells, and the occurrence of desensitization drug resistance is avoided. Therefore, the nano-polypeptide bionic fiber network antibody has a great prospect in application to tumor resistance, can efficiently inhibit the growth, invasion and metastasis of tumors, and has a wide application prospect.
Drawings
FIG. 1 is a graph of the results of mass spectrometry characterization of the self-assembled material prepared in example 1;
FIG. 2 is a transmission electron micrograph of the self-assembled nanoparticles prepared in example 2;
FIG. 3 is a transmission electron micrograph of the nanofiber prepared in example 2;
FIG. 4 is a confocal image of a SKBR-3 cell after co-incubation with a self-assembly material;
FIG. 5 is a scanning electron micrograph of the SKBR-3 cell model in example 4;
FIG. 6 is a graph showing the tumor growth inhibition of the mice in example 5;
FIG. 7 is a graph of survival of mice in example 5.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Example 1
In this embodiment, a bionic fiber network antibody self-assembly material is constructed, and the chemical structure of the bionic fiber network antibody self-assembly material is as follows:
the preparation method is synthesized according to a standard polypeptide solid phase synthesis method (SPPS).
The prepared self-assembly material is characterized by mass spectrum, and the mass spectrum characterization result is shown in figure 1, and can be known from figure 1: the main peak of the mass spectrogram can be seen to be consistent with the molecular weight of the synthesized polypeptide material, so that the synthesis of a target molecule is deduced, and the synthesis of the self-assembly material with the structure of the formula is shown to be successful.
Example 2
This example prepares a self-assembled nanoparticle solution and nanofiber dispersion of the product of example 1 by the following specific methods:
the self-assembly material prepared in example 1 was dissolved in DMSO solvent (concentration of self-assembly material was 3X 10)-3M), get 10 μ L above-mentioned solution and place in the centrifuging tube, again slowly add 990 μ L deionized water in the centrifuging tube, prepare out the mixed solution of water content 98%, characterize the self-assembling nanoparticle who obtains with transmission electron microscope self-assembling material monomer solution (water content 98%), the result is as shown in figure 2, can see by figure 2: the self-assembled material prepared in example 1 formed self-assembled particles in an aqueous solution.
Adding Her2 protein into the self-assembly nanoparticle solution obtained in the above step, wherein the concentration of Her2 protein is 3 x 10 after complete dissolution-8And M, standing for 48 hours to obtain the nanofiber dispersion liquid. The obtained nanofibers were characterized by transmission electron microscopy, and the results are shown in fig. 3, which shows that: the self-assembled polypeptide material becomes short fiber-like.
Example 3
Laser confocal test:
in the embodiment, human breast cancer SKBR-3 is taken as a cell model and cultured in DMEM medium containing 10 percent fetal bovine serum, 100U/mL penicillin and 100 mu g/mL streptomycin at the culture temperature of 37.0 ℃ and CO2The concentration of (2) was 5.0%. Culturing cells to logarithmic phase and good cell state, digesting dispersed cells with trypsin for 3min, centrifuging at 1000r/min for 3min, and discardingAnd (5) clear liquid. Will contain 10 per ml4The cell suspension of each cell was added to a confocal laser-induced cell dish, cultured for 24 hours, and then cultured in 1mL of a medium (3.0X 10) containing the self-assembly material prepared in example 1-5M) replacing the original culture solution, putting the original culture solution into a cell culture box for culturing for 2h, pouring out the supernatant, washing the supernatant for three times by PBS, adding a proper amount of PBS, and performing a single photon laser confocal imaging test. The test results are shown in fig. 4, and it can be seen from fig. 4 that: the strong green fluorescence appears on the surface of the cancer cell, which indicates that the self-assembly material can actively target the tumor cell.
Example 4
And (3) scanning electron microscope test:
in the embodiment, human breast cancer SKBR-3 is used as a cell model. The silicon wafer was placed on the bottom of the dish, and the control cells were cultured in DMEM medium containing 10% fetal bovine serum, 100U/mL penicillin and 100. mu.g/mL streptomycin for 24 hours, and the experimental cells were cultured in DMEM medium containing 10% fetal bovine serum, 100U/mL penicillin and 100. mu.g/mL streptomycin for 24 hours, followed by 1mL of the medium containing the self-assembly material prepared in example 1 (3.0X 10-5M) replacing the original culture solution, and culturing in a cell culture box at 37.0 deg.C and CO for 2 hr2Was 5.0%, cells were grown on the silicon wafer. The medium was then discarded, washed three times with PBS, fixed for 2h by adding 20% glutaraldehyde solution (glutaraldehyde: PBS buffer 1:4v/v), washed two times with PBS, then the cells were dehydrated in a gradient with 30%, 50%, 70%, 90%, 100% ethanol/PBS solution, twice for each concentration, 10min each time, and finally rinsed for 30min with tert-butanol. And (4) after the treatment, putting the cells into a vacuum drying oven for drying, and observing and scanning by using a scanning electron microscope after the drying is finished.
The test results are shown in fig. 5, from which it can be seen that: the surface of the tumor cells had fibrogenesis, which demonstrates that the self-assembled material of the present invention forms fibers on the surface of the tumor cells.
Example 5
Animal experiments:
the experiment meets the ethical requirements of national animals, and the experimental animals are Ba20 lb/c female nude mice were randomly divided into a control group and an experimental group, 10 mice were each group, pre-fed for 7 days, and inoculated with about 5X 10 cells at mammary gland sites of 20 mice6Establishing a mouse tumor model by using the SKBR-3 humanized breast cancer cells. When the tumor volume of the mouse is about 100mm3On the left and right, the administration treatment is started. The results of the experiment group mice administered with 200 μ L of the self-assembly material prepared in example 1 every 72 hours, the drug solution was dissolved in normal saline, the concentration was 100 μ M, the total administration was 7 times, the control group mice administered with 200 μ L of normal saline every 72 hours, the administration was 7 times, and the size of the tumor volume was observed, as shown in fig. 6 (V0 represents the tumor volume at the time of starting the administration treatment, V represents the tumor volume on days 2, 4, 6, 8, 10, 12, and 14), as can be seen from the figure: the self-assembly material can obviously inhibit the growth of tumors.
And a survival curve is drawn to observe the survival rate of the mouse, and the result is shown in figure 7, and the following can be seen in the figure: the self-assembly material can obviously improve the survival rate of mice.
The applicant states that the invention is illustrated by the above examples to the bionic fiber network antibody self-assembly material, the preparation method and the application thereof, but the invention is not limited to the above examples, that is, the invention is not meant to be implemented only by relying on the above examples. It should be understood by those skilled in the art that any modification of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.
SEQUENCE LISTING
<110> national center for Nano science
<120> bionic fiber network antibody self-assembly material, and preparation method and application thereof
<130> 2019
<160> 4
<170> PatentIn version 3.3
<210> 1
<211> 5
<212> PRT
<213> artificially synthesized sequence
<400> 1
Lys Leu Val Phe Phe
1 5
<210> 2
<211> 5
<212> PRT
<213> artificially synthesized sequence
<400> 2
Leu Pro Phe Phe Asp
1 5
<210> 3
<211> 3
<212> PRT
<213> artificially synthesized sequence
<400> 3
Asp Gly Arg
1
<210> 4
<211> 12
<212> PRT
<213> artificially synthesized sequence
<400> 4
Tyr Cys Asp Gly Phe Tyr Ala Cys Tyr Met Asp Val
1 5 10
Claims (3)
1. The bionic fiber network antibody self-assembly material is characterized by comprising an amido bondSequentially linked targeting units R3Fiber unit R2And a hydrophobic unit R1The three units are connected through amide bonds, and the chemical structure of the three units is shown as the formula (I):
R1-R2-R3formula (I);
wherein, R is1Has a chemical structure of
The dotted line represents the attachment site, said R2Derived from the polypeptide sequence Phe-Phe-Val-Asp-Phe, said R3From the polypeptide sequence Asp-Gly-Arg;
or, said R2Derived from the polypeptide sequence Lys-Leu-Val-Phe-Phe, said R3Derived from the polypeptide sequence Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val, said R1Has a chemical structure of
The dotted line indicates the attachment site;
or, said R2Derived from the polypeptide sequence Ile-Ser-Asp-Asn-Leu, said R3From the polypeptide sequence Asp-Gly-Arg, said R1Has a chemical structure of
The dotted line indicates the attachment site.
2. The preparation method of the bionic fiber network antibody self-assembly material of claim 1, wherein the preparation method comprises the following steps:
the bionic fiber network antibody self-assembly material is synthesized by taking amino acid with protected terminal amino group and side chain amino group and hydrophobic material as raw materials through a solid phase synthesis method.
3. The use of the biomimetic fiber network antibody self-assembly material according to claim 1 in the preparation of a medicament for inhibiting tumor growth, metastasis or invasion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910995134.4A CN110627912B (en) | 2019-10-18 | 2019-10-18 | A biomimetic fiber network antibody self-assembly material and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910995134.4A CN110627912B (en) | 2019-10-18 | 2019-10-18 | A biomimetic fiber network antibody self-assembly material and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110627912A CN110627912A (en) | 2019-12-31 |
| CN110627912B true CN110627912B (en) | 2022-03-08 |
Family
ID=68976798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910995134.4A Active CN110627912B (en) | 2019-10-18 | 2019-10-18 | A biomimetic fiber network antibody self-assembly material and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110627912B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113621028A (en) * | 2021-07-27 | 2021-11-09 | 南通大学 | Polypeptide self-assembly hydrogel bracket and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106749518A (en) * | 2016-11-10 | 2017-05-31 | 国家纳米科学中心 | A kind of polypeptide nano material containing double pyrenyl groups and its preparation method and application |
| CN106822036A (en) * | 2016-12-15 | 2017-06-13 | 国家纳米科学中心 | Special target self-assembling polypeptide nano-carrier, drug-loading nanoparticles and preparation method |
| CN108484733A (en) * | 2018-03-01 | 2018-09-04 | 国家纳米科学中心 | Amphiphilic targeting cell-penetrating peptide and its nano-probe, the drug-loading nanoparticles of self assembly |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122378A2 (en) * | 2011-03-08 | 2012-09-13 | The Trustees Of The University Of Pennsylvania | Antibody-like proteins for therapeutic and diagnostic use |
| CN106349331B (en) * | 2016-08-23 | 2020-05-15 | 国家纳米科学中心 | Bipyrene-based pH response self-assembly polypeptide nano material and preparation method and application thereof |
| CN107188929B (en) * | 2017-04-07 | 2019-09-10 | 中国石油大学(华东) | A kind of enzyme responsiveness self-assembling peptides and its application |
-
2019
- 2019-10-18 CN CN201910995134.4A patent/CN110627912B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106749518A (en) * | 2016-11-10 | 2017-05-31 | 国家纳米科学中心 | A kind of polypeptide nano material containing double pyrenyl groups and its preparation method and application |
| CN106822036A (en) * | 2016-12-15 | 2017-06-13 | 国家纳米科学中心 | Special target self-assembling polypeptide nano-carrier, drug-loading nanoparticles and preparation method |
| CN108484733A (en) * | 2018-03-01 | 2018-09-04 | 国家纳米科学中心 | Amphiphilic targeting cell-penetrating peptide and its nano-probe, the drug-loading nanoparticles of self assembly |
Non-Patent Citations (4)
| Title |
|---|
| An-Ping Xu等.Bio-inspired metal ions regulate the structure evolution of self-assembled peptide-based nanoparticles.《Nanoscale》.pubmed,2016,第8卷(第29期),第14078页右栏倒数第1段、图1，第14079页左栏第1段，第14082页左栏第2段. * |
| Bio-inspired metal ions regulate the structure evolution of self-assembled peptide-based nanoparticles;An-Ping Xu等;《Nanoscale》;pubmed;20160622;第8卷(第29期);第14078页右栏倒数第1段、图1，第14079页左栏第1段，第14082页左栏第2段 * |
| From carbon nanotechnology to bionanotechnology:Protein and peptide nanofibrils and nanowires;Oleg I.Kiselev等;《Carbon Nanotechnology》;Carbon Nanotechnology;20070509;第714页倒数第1段、第715页表1 * |
| Mitochondria-targeted delivery of doxorubicin to enhance antitumor activity with HER-2 peptide-mediated multifunctional pH-sensitive DQAsomes;Menghao Shi等;《International Journal of Nanomedicine》;pubmed;20180718;第13卷;第4210页右栏第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110627912A (en) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106822036B (en) | Specific targeting polypeptide self-assembly nano-carrier, drug-loaded nano-particle and preparation method | |
| CN103502262B (en) | Based on the Self-Assembled of double end peptide amphiphile | |
| CN106906230B (en) | Recombinant drug carrier protein gene and preparation method and application thereof | |
| CN106397545A (en) | Hydrogel material as well as preparation method and application thereof | |
| KR20200104524A (en) | Novel cell penetrating peptides and use thereof | |
| CN115192730A (en) | Bispecific polypeptide nano-drug targeting PD-L1 and preparation method and application thereof | |
| CN110627912B (en) | A biomimetic fiber network antibody self-assembly material and its preparation method and application | |
| CN105524139B (en) | High-activity tumor inhibitor and its preparing process and application | |
| CN111621288B (en) | Self-assembled material capable of forming nano defense network in situ of tumor, and preparation method and application thereof | |
| CN113512094A (en) | A collagen biomimetic material formed by self-assembly of covalently photocrosslinked polypeptides and covalently photocrosslinked polypeptides | |
| CN111494642B (en) | A kind of self-assembled material for in situ construction of artificial extracellular matrix, preparation method and application thereof | |
| CN113599504A (en) | Carrier-free protein intracellular delivery prodrug and preparation method and application thereof | |
| CN113797335B (en) | Polypeptide-based self-assembled photosensitive nanofiber material, preparation method thereof and application thereof in preparation of antitumor drugs | |
| CN106749518A (en) | A kind of polypeptide nano material containing double pyrenyl groups and its preparation method and application | |
| KR102274999B1 (en) | Novel cell penetrating peptides and use thereof | |
| CN109453364B (en) | A Dual Responsive Nanoparticle and Its Application in Tumor Suppression | |
| CN116327610B (en) | Botulinum toxin-like polypeptide nano-micelles and preparation method and application thereof | |
| KR102274876B1 (en) | Novel cell penetrating peptides and use thereof | |
| CN116063578A (en) | Preparation method and application of norovirus-derived nanoparticles as vaccine platform | |
| CN115093459A (en) | A delivery complex capable of axon-targeted modification on the surface of exosomes and its modification method for exosomes | |
| CN106957370A (en) | It is a kind of to trigger the polypeptide of toxicity in tumour cell | |
| CN115518152B (en) | Polypeptide micelles based on tumor vascular normalization and immune checkpoint blockade to enhance photoimmunotherapy and their preparation and application | |
| KR101923520B1 (en) | Self-assembled peptide nanostructures with structural diversity by thermodynamic control | |
| CN116355048B (en) | A polypeptide nanomaterial for targeted treatment of corneal neovascularization and its preparation method and application | |
| KR102274877B1 (en) | Novel cell penetrating peptides and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191231 Assignee: Zhongke guona Kangda (Beijing) Biotechnology Co.,Ltd. Assignor: NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY Contract record no.: X2021990000071 Denomination of invention: A bionic fiber network antibody self-assembly material and its preparation method and Application License type: Exclusive License Record date: 20210129 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221028 Address after: 102600 Room 309, Floor 3, Building 21, Yard 56, Simiao Road, Daxing Biomedical Industry Base, Zhongguancun Science and Technology Park, Daxing District, Beijing Patentee after: Zhongke guona Kangda (Beijing) Biotechnology Co.,Ltd. Address before: 100190 No. 11, north of Haidian District, Beijing, Zhongguancun Patentee before: NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY |
|
| TR01 | Transfer of patent right |